<DOC>
	<DOC>NCT00869089</DOC>
	<brief_summary>This trial will include: - Study period up to 7 months. - Office visits monthly lasting approximately 1 hour. - Blood Draws. - Oral medication that is taken 2 times daily. - Photographs and biopsies if agreed.</brief_summary>
	<brief_title>Safety and Efficacy of CC-10004 for Prurigo Nodularis</brief_title>
	<detailed_description />
	<mesh_term>Prurigo</mesh_term>
	<mesh_term>Neurodermatitis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Must understand and voluntarily sign an informed consent form Must be male or female and aged ≥ 18 years at time of consent Must be able to adhere to the study visit schedule and other protocol requirements Must have a diagnosis of prurigo nodularis based on clinical and histological findings and have failed four weeks of treatment with topical therapies, including corticosteroids and/or vitamin D derivatives. Must meet the following laboratory criteria: Hemoglobin WNL Hematocrit WNL White blood cell (WBC) count WNL Neutrophils ≥ 1500 /dL Platelets ≥ 100,000 /dL Serum creatinine ≤ 1.5 mg/dL Total bilirubin 2.0 mg/dL Aspartate transaminase (AST [serum glutamic oxaloacetic transaminase, SGOT]) and alanine transaminase (ALT [serum glutamate pyruvic transaminase, SGPT]) 1.5x upper limit of normal (ULN) Females of childbearing potential (FCBP) must have a negative urine pregnancy test at screening (Visit Must have a negative purified protein derivative (PPD) within 28 days of the baseline visit. Must have a negative purified protein derivative (PPD) within 28 days of the baseline visit. History of cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major diseases deemed clinically significant by the investigator Any systemic treatment (including ultraviolet light, corticosteroids, thalidomide, azathioprine, cyclosporine) within 28 days of study drug administration. Any topical treatments (including corticosteroids, vitamin D derivatives) within 14 days of study drug initiation. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. Pregnant or lactating female.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>PN</keyword>
</DOC>